Evaluates SPECT imaging of technetium-99m complexes targeting prostate-specific membrane antigen in cancer cells, suggesting their potential in disease targeting.
We report the design and synthesis of new conjugates (H₂L1-4) consisting of a bifunctional bis(thiosemicarbazone) chelator conjugated to prostate-specific membrane antigen pharmacophores. Radiolabeling H₂L1-4 with the 99mTc nitrido core in a one-pot synthesis at 95 °C for 10 min produced the complexes [99mTc][TcN(L1-4)] with high radiochemical purity (RCP > 95%) and excellent stability. In vitro evaluation of the [99mTc]Tc PSMA complexes demonstrated high cell-surface receptor binding and internalization in cancer cells expressing PSMA (PSMA+), which was inhibited by an excess of a PSMA-specific inhibitor. The most lipophilic of the complexes, [99mTc][TcN(L2)], also showed significant nonspecific uptake in the control cell line (PSMA-). SPECT-CT imaging of the four complexes, at 1 and 4 h postinjection and biodistribution studies at 5 h postinjection in BALB/c nude mice with both PSMA+ and PSMA- tumors, demonstrated significant differences in the receptor-specific tumor uptake and clearance pathways. [99mTc][TcN(L3)] and the bivalent [99mTc][TcN(L4)] showed predominantly renal clearance and the highest PSMA+ tumor uptake and retention. Conversely, [99mTc][TcN(L1)] and [99mTc][TcN(L2)] displayed gastrointestinal clearance and lower PSMA+ tumor uptake. The work demonstrates that bis(thiosemicarbazones) are effective bifunctional chelators for the development of 99mTc radiopharmaceuticals targeting PSMA with the potential to be easily modified to target other diseases.
No takes yet. Share an insight, caveat, or question.
Maclean et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: